The metastasis-associated protein 1 (MTA1) is overexpressed in various human cancers and is closely connected with aggressive phenotypes; however, little is known about the transcriptional regulation of the MTA1 gene. This study identified the MTA1 gene as a target of p53-mediated transrepression. The MTA1 promoter contains two putative p53 response elements (p53REs), which were repressed by the p53-inducing drug 5-fluorouracil (5-FU). Notably, 5-FU treatment decreased MTA1 expression only in p53 wild-type cells. p53 and histone deacetylases 1/2 were recruited, and acetylation of H3K9 was decreased on the promoter region including the p53REs after 5-FU treatment. Proteomics analysis of the p53 repressor complex, which was pulled down by the MTA1 promoter, revealed that the poly(ADP-ribose) polymerase 1 (PARP-1) was part of the complex. Interestingly, p53 was poly(ADP-ribose)ylated by PARP-1, and the p53-mediated transrepression of the MTA1 gene required poly(ADP-ribose)ylation of p53. In summary, we report a novel function for poly(ADP-ribose)ylation of p53 in the gene-specific regulation of the transcriptional mode of p53 on the promoter of MTA1.
Introduction
The metastasis-associated protein 1 (MTA1) is a component of the nucleosome remodeling and deacetylation complex, which functions as a transcriptional repressor (Denslow and Wade, 2007) . MTA1 is regarded as a candidate metastasis-associated gene, as it is overexpressed in various human cancers, such as breast, gastrointestinal, prostate and hepatic cancers, the pathophysiological features of which correlate well with tumorigenesis characterized by invasion and metastasis (Toh and Nicolson, 2009) . Recently, we and others provided molecular links that connect the overexpression of MTA1 with progression to malignancy. MTA1 binds to and activates the hypoxia-inducible factor-1 alpha , an important transcriptional regulator under hypoxia, which promotes the metastatic potential of cancer cells (Moon et al., 2006; Yoo et al., 2006) . The MTA1 protein is stabilized by DNA damage induced by ionizing or ultra violet radiation, leading to deregulation of the DNA damage repair system, which comprises p53, p21/WAF, and ATR (Li et al., 2009a (Li et al., , b, 2010a . Importantly, knockdown of MTA1-suppressed cell migration and invasion, which reversed the malignant phenotypes in vitro, and delayed tumor development in mouse xenografts (Qian et al., 2005; Kai et al., 2011) . Recent research focused on the study of the external and internal stimuli that activate MTA1 and the associated molecular mechanism; however, these are not fully understood. Previously, it was reported that heregulin b1, hypoxia and the hepatitis B virus X protein (HBx) activate the transcription of MTA1 in normal and cancer cells (Mazumdar et al., 2001; Yoo et al., 2006; Yoo et al., 2008) .
The tumor suppressor p53 is the best-studied transcriptional factor and has a broad spectrum of functions in cellular physiology, including cell-cycle arrest, apoptosis, DNA repair and autophagy (Vousden and Lane, 2007) . Recently, several reports indicated that p53 is also involved in cancer progression by regulating cancer invasion and metastasis specifically. Wild-type p53 induced mouse double-minute-2-mediated degradation of Slug, which is a member of the Snail family of zinc-finger transcription factors that represses E-cadherin expression, resulting in the suppression of cancer cell invasion (Wang et al., 2009a, b) . p53 repressed the transcriptional expression of CD44, which is a transmembrane cell-surface protein that promotes tumor growth and metastasis (Godar et al., 2008) . Moreover, loss of p53 function enhanced invasion and metastasis in a number of in vivo models of metastatic pancreatic tumors and hepatocellular carcinoma (Lewis et al., 2005; Morton et al., 2008) , which suggests that p53 is involved in the regulation of many metastasis-associated genes, which probably include MTA1. p53 facilitates transcriptionally positive or negative regulation of gene expression. The well-defined p53-associated activating complexes usually include histone acetyltransferases (HATs), such as the CREBbinding protein, p300 and p300/CBP-associated factor, and induce the transcriptional expression of genes such as p21, GADD45a and BCL2-associated X protein (BAX) (Riley et al., 2008) . p53 also trans-represses the expression of genes associated with oncogenesis and cancer progression, such as survivin and the vascular endothelial growth factor (VEGF). However, functional differences between the trans-activating and transrepressing complexes of p53, and their DNA-binding elements are important to understand p53 function fully. Posttranslational modifications, such as phosphorylation, acetylation and ubiquitination, are also considered as important factors that lead to alteration of the transcriptional activity of p53. In addition, p53 is a substrate for O-linked N-acetylglucosamine glycosylation and prolyl isomerization, which function in the regulation of the stability and transactivation activity of the protein (Meek and Anderson, 2009 ). Posttranslational modification of p53 has been extended to include poly(ADP-ribose)ylation (PARylation); however, its role in the transcriptional function of p53 is poorly understood (Wesierska-Gadek et al., 1996; Kumari et al., 1998; Simbulan-Rosenthal et al., 1999) .
In the present study, we investigated the molecular details of the regulation of the expression of MTA1. We found that p53 trans-repressed the expression of the MTA1 gene via the p53-binding elements located in its upstream promoter. Moreover, p53 was PARylated directly by polymerase 1 (PARP-1) when it formed a p53-associated repressing complex with histone deacetylase (HDAC) 1 and HDAC2 on the MTA1 promoter. Hence, here we report that MTA1 is a new target gene of p53 and that PARylation of p53 has an important function in the p53-mediated repression of the expression of the MTA1 gene.
Results

MTA1 promoter activity is repressed by p53
Although MTA1 is a well-defined metastatic and angiogenic factor, the molecular details of the regulation of its expression are not understood fully. To investigate the transcriptional regulators of MTA1 expression, potential cis elements located in the 5 0 -upstream promoter sequences relative to the transcription initiation site of the MTA1 gene were analyzed using MatInspector (Cartharius et al., 2005) . Interestingly, three putative p53-response elements, p53RE1, p53RE2 and p53RE3, were located in this promoter region ( Figure 1a) . We cloned the 1 kb 5 0 -upstream promoter and constructed an MTA1 promoter reporter gene. 5-Fluorouracil (5-FU), which is an anticancer agent that induces p53, was tested for its potential to modulate the MTA1 promoter. First, deletion of p53RE1 and p53RE2 largely increased basal-level activity, indicating that the p53REs are involved in the regulation of MTA1 expression. Second, the activities of both the 1 kb and 0.5 kb promoter reporters were decreased after 5-FU treatment, in a dose-dependent manner, indicating that p53RE3 is also associated with the regulation of the MTA1 gene (Figure 1a) . Consistently, the expression levels of the MTA1 protein and mRNA were decreased considerably in MCF-7 and HepG2 cells, whereas that of p53 was increased dramatically after 5-FU treatment (Figure 1b and Supplementary Figure 1A) . The involvement of p53 in the 5-FU-mediated repression of MTA1 was confirmed by the observation that overexpression of p53 repressed the expression of MTA1 (Figure 1c and Supplementary Figure 1B) , whereas knockdown of p53 using si-RNA recovered the levels of the MTA1 protein The MTA1 promoter contains p53REs that repress the transcriptional expression of MTA1 We characterized the p53REs located in the MTA1 promoter further using various protein-DNA binding analysis ( Figure 3a ). Chromatin immunoprecipitation (ChIP) assays, using specific p53 antibodies, demonstrated clearly that p53 bound to a region containing p53RE1 and p53RE2 (ChIP1), and to another region containing p53RE3 (ChIP2). The specificity of these bindings was demonstrated using anti-Myc antibody that detected Myc-tagged p53 introduced exogenously ( Figure 3b ). Next, we performed DNA pull-down assays using biotin end-labeled double-stranded oligonucleotide probes encoding p53REs and their mutants. Binding of p53 was detected clearly using the two wild-type probes, Pull1 and Pull2, and was diminished by the addition of an anti-p53 antibody, PAb240. p53 binding to the three probes encoding the mutant types was decreased, indicating the specific binding of p53 to these elements (Figures 3c and d ). Electrophoretic mobility shift assay (EMSA) demonstrated further that the recombinant p53 protein specifically bound to p53RE2 and p53RE3, but not to p53RE1 (Figure 3e ). Finally, we examined whether the 5-FU-induced repression of MTA1 was associated with the binding of p53 to the MTA1 promoter. ChIP analysis showed that binding of p53 on the p53REs was significantly increased in the presence of 5-FU. Concomitantly, bindings of HDAC1 and HDAC2 were increased transiently, and acetylation of H3K9 was decreased ( Figure 3f ). These results were confirmed by EMSA and DNA pull-down assays that showed increased binding of p53 complex, HDAC1 and HDAC2 to the p53RE2 and p53RE3 upon 5-FU treatment (Figures 3g and h ). Together, these results suggest that the binding of a p53 repressor complex including HDACs to the p53RE2 and p53RE3s on the MTA1 promoter induces the transcriptional repression of the MTA1 gene after 5-FU treatment.
PARylation of p53 induced by PARP-1 is required for repression of MTA1
To characterize further the p53 repressor complex on the MTA1 promoter, the proteins that were pulled down from nuclear extracts of HepG2 cells were subjected to proteomics analysis using a combination of liquid chromatography-tandem mass spectrometry (LC-MS/MS). Among the proteins identified, PARP-1 recorded the most hits with the highest probable score (Figure 4a ). The binding of PARP-1 to the MTA1 promoter was verified using western blotting (Figure 4b) . Interestingly, the binding of PARP-1 to the MTA1 promoter regions ChIP1 and ChIP2 increased dramatically after 5-FU treatment, suggesting that the biological function of 5-FU may involve the binding of PARP-1 to the MTA1 promoter ( Figure 4c) .
Next, we investigated whether PARylation of p53 was involved in the repressive function of p53 on the MTA1 promoter. First, we found that immunoprecipitated p53 was recognized by specific anti-PAR antibodies, demonstrating that the p53 protein was PARylated (lane 4, Figure 5a ). 5-FU treatment increased the level of PARylated p53; in contrast, 6-(5H)-phenanthridinone (PHEN), which is an inhibitor of PARP-1, decreased the level of PARylated p53 (lanes 5 and 6, Figure 5a ). As p53 interacts directly with HDAC1 to exert its repressive function, we examined whether PARylation of p53 affected the binding of p53 to HDAC1 (Juan et al., 2000) . Binding of p53 to HDAC1 was detected in the presence of 5-FU; however, this binding was abolished in the presence of PHEN (Figure 5b) . Similarly, the binding of p53, HDAC1 and HDAC2 to the MTA1 promoter, which was increased after 5-FU treatment, was diminished in the presence of PHEN (Figure 5c ). Taken together, these data suggest that p53 is PARylated by PARP-1 in the presence of 5-FU and that PARylated p53 forms a repressor complex with HDAC1 and HDAC2 on the MTA1 promoter, resulting in the repression of the MTA1 gene. A similar increase of the binding of p53 was observed on the survivin promoter, which is a target of the repressive function of p53 (Wang et al., 2010) (Figure 5d ). Furthermore, PHEN decreased the binding of p53 to the survivin promoter, which may represent a transcriptional derepression that is consistent with the recovery of the 5-FU-mediated repression of survivin after PHEN treatment. These observations were largely in contrast with the observation of binding of p53 to the promoters of p21 and BAX, which are targets of the activating function of p53 (Riley et al., 2008) . The binding of p53 to these promoters was enhanced further by PARP-1 inhibition in cells exhibiting suppression of the induction of mRNA levels by PARP-1 inhibition (Supplementary Figure 3) . (Figure 6a ). Finally, we showed that knockdown of either p53 or PARP-1 increased the levels of the HIF-1a and VEGF, and it further prevented the 5-FU-induced decrease in the level of HIF-1a and VEGF (Figure 6b and Supplementary  Figure 4) . Finally, we demonstrated the potential importance of our findings in the MTA1-mediated cell migration. We carried out MTA1 knockdown experiments in the wild-type HCT116 (p53 þ / þ ) and isogenic derivative HCT116 (p53 À/À ) cells. The conditionedmedia obtained from the MTA1-knocked down HCT116 (p53 þ / þ ) induced a less motility of human dermal fibroblasts (45% wound closure at 12 h) to compare with that from the control HCT116 (p53 þ / þ ) (71% wound closure at 12 h), indicating that MTA1 is involved in the cell migration. The migration of human dermal fibroblasts was more prominent with the conditioned-media obtained from HCT116 (p53 À/À ) (81% wound closure at 12 h), whereas it was inhibited by the media obtained from the knockdown of MTA1 in HCT116 (p53 À/À ) (46% wound closure at 12 h) (Figure 6c ). This result suggests that p53 affects the MTA1-mediated cell motility. Taken together, our results demonstrated that p53 functionally repressed the transcriptional expression of the MTA1 gene via binding to the p53REs, which was facilitated by PARP-1-mediated PARylation of p53 (Figure 6d ).
Discussion
Upregulation of MTA1 is implicated in malignancy of cancer cells, providing a notion of the global deregulation of MTA1 expression in cancer cells. Herein, we demonstrated that the tumor suppressor p53 has a vital role in the repression of the expression of MTA1. Interestingly, the p53-mediated trans-repression of the MTA1 gene required PARylation of p53, which was (a) Whole cell lysates were immunoprecipitated (IP) with normal IgG or anti-p53 antibodies, and precipitates were probed by western blotting (WB), using an anti-PAR antibody. Arrow indicates p53 that was verified by WB. The membrane was stripped and reprobed with an anti-p53 antibody as control. (b) Whole cell lysates were immunoprecipitated with normal IgG or anti-p53 antibodies, and precipitates were probed by WB using an anti-HDAC1 antibody. The membrane was stripped and reprobed with an anti-p53 antibody as control. (c) DNA fragments that immunoprecipitated by anti-p53, anti-HDAC1 or anti-HDAC2 antibodies were amplified by PCR with primers for ChIP1 and ChIP2. (d) DNA fragments that immunoprecipitated by normal IgG or antip53 antibodies, were amplified by PCR using primers for the promoter regions containing p53 response elements for survivin (À181 to þ 81), p21 (À1688 to À1335), or Bax (À883 to À455).
catalyzed by PARP-1. The observation that PARylation is a significant posttranslational modification of p53 that alters the transcriptional activity for a new target gene, MTA1, as well as the well-known target genes survivin, p21, and BAX, is a novel finding.
Although PARP-1 is an abundant nuclear enzyme that has important roles in DNA repair, recent studies have demonstrated its function in gene-specific epigenetic regulation. PARP-1 PARylates directly chromatinassociated proteins, including histone variants, chromatin-modifying enzymes, and transcriptional factors (Kraus, 2008) . PARP-1 targets the p53 protein, resulting in PARylated p53; however, the effect of PARylation on the biological function of p53 is poorly understood (Wesierska-Gadek et al., 1996; Kumari et al., 1998; Simbulan-Rosenthal et al., 1999) . Limited observations suggest that PARylation of p53 regulates the DNAbinding properties or the localization of p53 (MendozaAlvarez and Alvarez-Gonzalez, 2001; Kanai et al., 2007) . In this study, we report a novel function of PARylated p53: involvement in gene-specific regulation of the transcriptional mode of p53. Surprisingly, PARP-1 inhibition, using PHEN, resulted in differential perturbation of the binding of p53 to the promoters of target genes ( Figure 5 ). PHEN treatment inhibited p53 binding to the promoters of MTA1 and survivin, which are regulated in the trans-repression mode, whereas it increased p53 binding to the promoters of p21 and BAX, which are regulated in the trans-activation mode (Figure 5d ). Interestingly, we found that PARylation of p53 was barely detectable in MDA-MB-231 that has a mutated p53 (Supplementary Figure 5a) . 5-FU treatment did not increase, or even decrease, the level of p53 PARylation in MDA-MB-231cells, and the mutant p53 did not bind to the MTA1 promoter ( Supplementary  Figures 5B and 5C ).
In general, PAR has a higher negative charge density than DNA; therefore, PARylation of proteins may affect protein-protein and protein-DNA interactions (Kim et al., 2005) . However, the molecular details of the mechanism via which PARylation of p53 specifies transcriptional outcome remain an open question. Recent research may provide several potential answers to this question. First, chromatin dynamics induced by PARylated p53 may promote the recruitment of differential transcriptional coactivators onto target genes. Mehrotra et al. (2011) reported that PARP-14 regulates STAT6-dependent transactivation by switching HDACs to HAT coactivators on the promoter of the target gene, Fcer2a. Second, PARylation of p53 may be linked to DNA methylation, which is essential for specific patterns of gene expression during tumor development. Although a link to PARylation was not established, p53 and DNMT1 may cooperate toward the trans-repression of the p53 target genes survivin and CDC25C (Este`ve et al., 2005) . Inhibition of the PARylation process via either the chemical inhibitor 3-aminobenzamide or the ectopic overexpression of poly (ADP-ribose) glycohydrolase altered the pattern of DNA methylation in the promoter of the HTF9 or DNMT1 genes (Zardo and Caiafa, 1998; Zampieri et al., 2009) . Finally, DNA sequences for p53 binding may distinguish between PARylated and non-PARylated p53. p53 response elements differ largely regarding the number of copies of the consensus motif and in the pattern of the array. Wang et al. (2009a, b) demonstrated that activating p53REs are the canonical sequences, whereas repressing p53REs are noncanonical. We found that the p53REs located in the MTA1 promoter are similar to the noncanonical p53RE of the survivin promoter, which is apparently different from the canonical p53REs of the promoters of BAX or p21 (Riley et al., 2008; Wang et al., 2009a, b) . Further experimental evidences are necessary to clarify the mechanisms proposed and will promote a better understanding of the differential transcriptional functions of p53 and PARP-1.
5-FU has been used widely in the treatment of a broad spectrum of cancers, including colorectal and breast cancers. 5-FU induces a shortage of pyrimidine nucleotides, and, more importantly, induces p53 (Longley et al., 2003) . Here, we demonstrated that MTA1 is a novel target of 5-FU-induced p53. 5-FU repressed the expression of MTA1 efficiently via induction of p53, thereby abolishing the stability of the MTA1-induced HIF-1a protein and downregulating VEGF (Figure 6 ). These findings are also observed in a clinical setting, as the global transcript profiles of 5-FU-based chemoradiotherapy colorectal adenocarcinoma samples exhibited more repressed expression of the MTA1, VEGF and survivin genes compared with that observed in nontreated or short-course radiotherapy samples (Petty et al., 2009) . Taken together, these observations indicate that the repression of MTA1 may represent an important mechanism underlying the anticancer effects of 5-FU treatment.
As PARPs are activated by DNA-damaging chemotherapy and irradiative radiation, these molecules are attractive therapeutic targets for cancer treatment (Krishnakumar and Kraus, 2010) . Therefore, PARP inhibitors are developed to target a wide spectrum of cancers or to sensitize cancer cells to anticancer therapy. A variety of PARP-1 inhibitors, including Iniparib, Olaparib and Veliparib, are currently in clinical trials (Yap et al., 2011) . However, much attention should be given to our observation that knockdown or chemical inhibition of PARP1 decreased the 5-FU-induced p53 binding on the promoter of MTA1, and subsequently recovered the expression level of the MTA1 gene (Figures 5c and 6a) . Similarly, PARP-1 interacts with and PARylates other transcription factors, such as SMAD3/4 and the Kruppel-like factor 8, thereby regulating their target genes (Lo¨nn et al., 2010; Lu et al., 2011) . These observations indicate that inhibition of PARP-1 may cause disturbances in gene expression that may drive the stimulation of a genetic network that enhances oncogenic potential. More intriguingly, several preclinical studies have reported that PARP inhibitors are more effective in BRCA-deficient cells than in wild-type BRCA cells (Yap et al., 2011) . Furthermore, a recent trial showed that iniparib failed to prolong survival in metastatic, triple-negative breast cancer (O'Shaughnessy et al., 2011) . These findings may raise issues regarding the spectrum of clinical application of PARP-1 inhibitors, which may be related to our finding of gene-specific regulation mediated by PARylated p53.
Materials and methods
Cells and cell culture
Chang, WRL-68, MCF7, MDA-MB-231, Hep3B and HepG2 cell lines were obtained from American Type Culture Collection. HCT116 and p53 isogenic derivative colon cancer cells were kindly provided by Dr Bert Vogelstein (The Johns Hopkins University School of Medicine, Baltimore, MD, USA). Wild-type and p53-deficient MEFs were as reported previously (Sung et al., 2010) . MEFs were used at passages 3-5. Cells were maintained in either Dulbecco's Modified Eagle's Medium or McCoy's 5A Medium containing 10% fetal bovine serum in an incubator with 5% CO 2 and 95% air at 37 1C. 5-FU and PHEN were purchased from Sigma-Aldrich (St Louis, MO, USA).
Plasmids, si-RNA, and transient transfection The p53 eukaryotic expression vector was provided by Dr Bert Vogelstein (The Johns Hopkins University School of Medicine) and subcloned into the pCMV-Myc vector. The MTA1 promoter (À860 to þ 216 relative to the transcription initiation site) was cloned from a human BAC genomic clone (RZPD, Berlin, Germany) via PCR amplification and subsequent insertion into the SacI/NheI site of the pGL2-Basic vector (Promega, Madison, WI, USA). The si-RNA duplexes targeting p53, and control nonspecific si-RNA were synthesized and purified by ST Pharm (Porta et al., 2005; Yoo et al., 2008) . Si-PARP-1 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Transient transfection and reporter gene analysis were performed, as described previously (Yoo et al., 2008) . The significance of any differences was determined using Student's t-tests and was expressed as a probability value. Mean differences were considered significant at Po0.05.
Western blot analysis, immunoprecipitation and RT-PCR Western blotting and immunoprecipitation were carried out, as described previously, using specific antibodies against MTA1, p53 (DO-1), PARP-1, HDAC-1, HDAC-2 (Santa Cruz), PAR (Trevigen, Gaithersburg, MD, USA), or a-tubulin (Calbiochem, La Jolla, CA, USA) (Yoo et al., 2008) . RT-PCR was carried out, as described previously with specific primers (Yoo et al., 2008) (Supplementary Table) .
Immunoprecipitation and ChIP Assay Immunoprecipitation was performed as described previously using normal mouse IgG or an anti-p53 antibody (DO-1) and probed using anti-PAR or anti-HDAC1 antibodies (Yoo et al., 2008) . The ChIP assay was performed, as described previously, using specific antibodies against p53, HDAC1, HDAC2, AcH3K9 (Abcam, Cambridge, MA, UK) and PARP-1 (Santa Cruz) (Na et al., 2009) . Bound target DNA fragments (À718 to À348 for ChIP1 and þ 89 to þ 366 for ChIP2) were detected using PCR. The primers used to amplify DNA fragments including the p53 response elements in the promoter of p21 and BAX were described in Supplementary Table. DNA pull-down assays and proteomics MTA1 promoter templates biotinylated at the 5 0 -end of the forward strand (À547 to À423 for Pull1 and þ 89 to þ 336 for Pull2) were produced using PCR. Nuclear extracts were prepared as described previously (Na et al., 2009) . One hundred micrograms of nuclear extracts were incubated with a 10-nm biotinylated DNA probe in a binding buffer (20 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.01% NP-40, and protease inhibitor cocktail) containing 1 mg/ml of herringsperm DNA and 20 ml of streptavidin-sepharose at 4 1C overnight. The protein-DNA complexes were washed three times with binding buffer and were subjected to SDS-PAGE followed by western blotting using anti-p53, anti-PARP-1, anti-HDAC1 or anti-HDAC2 antibodies (Santa Cruz).
For LC-MS/MS analysis, pulled down proteins were fractionated using SDS-PAGE. Protein bands were excised, in-gel digested with trypsin, and analyzed further, using LC-MS/MS on a ThermoFinnigan LTQ ion-trap mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) coupled to an Agilent 1200 series capillary chromatographic system. Samples were suspended in 0.4% acetic acid (v/v) and separated on a reverse-phase C18 column (75 mm id Â 150 mm) prepared in-house in a 40-min linear gradient containing 5-40% acetonitrile and 0.1% formic acid at a flow rate of 0.4 ml/min. The mass spectrum was acquired using data-dependent mass transition with dynamic exclusion for 30 s. Analytical events consisted of four consecutive full MS scans in a range of m/z 300-2000, followed by three MS2 scans of the 3 most intense peptide ions. LC-MS/MS data were used to search the IPI human protein database using the SEQUEST algorithm incorporated into the BioWorks software (version 3.2) (Thermo Electron, San Jose, CA, USA).
Electrophoretic mobility shift assay Recombinant p53 proteins (Santa Cruz) or nuclear extracts obtained from HepG2 cells were incubated in the presence or absence of 100-or 200-fold excess of cold probe at room temperature in a reaction buffer containing 10 ng of poly(dI-dC) and 100 mg/ml of BSA in 20 mM HEPES (pH 7.8), 25 mM KCl, 10% glycerol, 2 mM MgCl 2 , 0.1 M EDTA, 0.02% NP-40, and 1 mM DTT. After a 10 min of preincubation at room temperature, 80 fmol radioactively labeled DNA probe was added, and the incubation was continued for another 20 min. Samples were fractionated on a 6% native polyacrylamide gel. The sequences of oligonucleotides used for EMSA are shown in Supplementary Table. Cell migration assay Wild-type HCT116 (p53 þ / þ ) and HCT116 (p53 À/À ) cells were transfected with si-GFP or si-MTA1. After 24 h of transfection, cultured media were collected for migration assay. The culture insert (Ibidi, Martinsried, Germany) was placed into m-Dish and slightly pressed on the top to ensure tight adhesion. An equal number of human dermal fibroblasts were added into the two reservoirs of the same insert and incubated at 37 1C/5% CO 2 . After 24 h, media were changed with the conditioned-media and the insert was gently removed to create a gap of B500 mm. Cells migrating into the gap region were monitored with a microscope. Area of wound was quantified by ImageJ software (http://rsb.info.nih.gov) and the percent of wound closure was determined.
